Nurix Therapeutics' NX-5948 shows promise in Waldenstrom's macroglobulinaemia trial

By Yahoo! Finance | Oct 21, 2024 at 05:51 AM EST

Nurix Therapeutics shared positive clinical results of NX-5948, a BTK degrader for treating Waldenstrom's macroglobulinemia, at a workshop in Prague. The trial demonstrated safety and efficacy in patients, supporting its advancement to Phase 1b.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.